Journal of Oncology / 2021 / Article / Tab 2

Research Article

Comparative Recurrence Analysis of Pancreatic Adenocarcinoma after Resection

Table 2

Pairwise comparison of survival for different tumor progression patterns.

Recurrence patternsWhole cohortHead
OSApsPFSOSApsPFS
Mst95%CIMst95%CIMst95%CIMst95%CIMst95%CIMst95%CI

Local progressionReference29.3724.47–39.5715.9311.07–25.038.976.40–10.5727.6024.47–37.2315.939.13–21.539.136.90–10.80
Liver-only metastasis20.117.37–24.630.21412.609.83–15.770.4445.034.07–6.470.01420.4017.37–27.900.41312.139.83–15.770.5455.474.20–6.500.050
Lung-only metastasis17.3315.33–52.570.58214.7014.00–30.430.5815.472.80–7.470.68017.3015.33–33.300.41314.7014.00–17.100.4432.872.63–10.600.720
Other metastases23.9710.77–23.970.86311.231.63–29.450.15412.739.13–28.700.23916.1313.55–18.270.538NANANA12.1310.24–15.270.532
Local + distant metastasis24.878.50–34.870.2477.203.67–11.570.1155.601.73–7.600.02524.1110.13–30.220.0944.172.63–11.570.0786.532.10–8.670.089
Multiple metastases17.5011.20–19.500.0069.208.10–12.630.0235.703.80–8.300.01717.5013.80–19.500.0499.208.10–12.630.1215.702.70–8.630.023
Liver-only metastasisReference20.117.37–24.6312.609.83–15.775.034.07–6.4720.4017.37–27.9012.139.83–15.775.474.20–6.50
Lung-only metastasis17.3315.33–52.570.9214.7014.00–30.430.6765.472.80–7.470.28517.3015.33–33.300.62714.7014.00–17.100.7522.872.63–10.600.496
Other metastases23.9710.77–23.970.56211.231.63–29.450.22512.739.13–28.700.03616.1313.55–18.270.452NANANA12.1310.24–15.270.250
Local + distant metastasis24.878.50–34.870.477.203.67–11.570.2865.601.73–7.600.93124.1110.13–30.220.4794.172.63–11.570.1716.532.10–8.670.773
Multiple metastases17.5011.20–19.500.0829.208.10–12.630.0925.703.80–8.300.07617.5013.80–19.500.1499.208.10–12.630.2405.702.70–8.630.855
Lung-only metastasisReference17.3315.33–52.5714.7014.00–30.435.472.80–7.4717.3015.33–33.3014.7014.00–17.102.872.63–10.60
Other metastases23.9710.77–23.970.67811.231.63–29.450.12512.739.13–28.700.30916.1313.55–18.270.558NANANA12.1310.24–15.270.326
Local + distant metastasis24.878.50–34.870.4917.203.67–11.570.4365.601.73–7.600.06124.1110.13–30.220.5534.172.63–11.570.4086.532.10–8.670.799
Multiple metastases17.5011.20–19.500.2759.208.10–12.630.0225.703.80–8.300.57717.5013.80–19.500.7189.208.10–12.630.0255.702.70–8.630.734
Other metastasesReference23.9710.77–23.9711.231.63–29.4512.739.13–28.7016.1313.55–18.27NANA12.1310.24–15.27
Local + distant metastasis24.878.50–34.870.3347.203.67–11.570.6865.601.73–7.600.01624.1110.13–30.220.2734.172.63–11.57NA6.532.10–8.670.223
Multiple metastases17.5011.20–19.500.1089.208.10–12.630.9985.703.80–8.300.00217.5013.80–19.500.6179.208.10–12.63NA5.702.70–8.630.030
Local + distant metastasisReference24.878.50–34.877.203.67–11.575.601.73–7.6024.1110.13–30.224.172.63–11.576.532.10–8.67
Multiple metastases17.5011.20–19.500.7019.208.10–12.630.9585.703.80–8.300.91017.5013.80–19.500.8799.208.10–12.630.7705.702.70–8.630.637

NA, not available; other abbreviations as in Table 1.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.